Subcutaneous administration of polymerized type I collagen downregulates interleukin (IL)-17A, IL-22 and transforming growth factor-β1 expression, and increases Foxp3-expressing cells in localized scleroderma: Polymerized type I collagen for treatment of LS

Furuzawa-Carballeda, J. ; Ortíz-Ávalos, M. ; Lima, G. ; Jurado-Santa Cruz, F. ; Llorente, L.

Clinical and experimental dermatology, 2012-08, Vol.37 (6), p.599-609 [Periódico revisado por pares]

Texto completo disponível